Clinical Trials Directory

Trials / Completed

CompletedNCT00634361

Ethyl-EPA Treatment of Prodromal Patients

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
7 (actual)
Sponsor
Yale University · Academic / Other
Sex
All
Age
14 Years – 35 Years
Healthy volunteers
Not accepted

Summary

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Conditions

Interventions

TypeNameDescription
DRUGethyl-eicosapentaenoic acid2 mg per day

Timeline

Start date
2001-09-01
Primary completion
2005-08-01
Completion
2005-08-01
First posted
2008-03-13
Last updated
2014-05-22

Source: ClinicalTrials.gov record NCT00634361. Inclusion in this directory is not an endorsement.

Ethyl-EPA Treatment of Prodromal Patients (NCT00634361) · Clinical Trials Directory